Tectonic Therapeutic Inc. Common Stock (TECX)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Tectonic Therapeutic as a Graham-style analyst would: the filed figures show no revenue, and losses are persistent. Net loss was $42.8M in FY2023, $58.0M in FY2024, and $74.2M in FY2025; fiscal Q1 2026 lost $25.2M and fiscal Q2 2026 lost $22.3M. That is not an earnings record I can value, and FairStock's Lynch category is 'none' because every one of the last four years was a loss. The business may have scientific promise in GPCR-targeted biologics and the TX45 relaxin candidate, but a durable moat is unproven at this stage. Financial health is mixed: debt is tiny at D/E 0.02, and FairStock's Altman Z-score is 17.37, yet trailing free cash flow is -$72.4M and FairStock's FCF yield is -18.6%. FairStock's Piotroski score is 2/9, ROE is -33.80%, ROCE is -22.29%, and its overall FairStock Score is 26/100, all signs of weak current economics. At the 2026-10-26 close of $19.95 and $390M market cap, FairStock calculates P/E at -4.37 and P/B at 1.71; a negative P/E gives no conventional earnings valuation, and 1.71 times book is not a deep asset bargain. The 52-week range of $15.52-$39.53 shows how sentiment swings. Growth is pipeline-dependent, not commercial: revenue growth is N/A and profit growth is -11.51%. I would want evidence of clinical progress, cash runway, and controlled spending before calling this a margin-of-safety investment.

In plain English: Tectonic Therapeutic is a small biotechnology company developing protein-based medicines, including a lead candidate called TX45, but its filed figures show no revenue. The business looks weak today because it has been losing money: net losses were $42.8 million in fiscal 2023, $58.0 million in fiscal 2024, and $74.2 million in fiscal 2025. At $19.95 a share, the price looks expensive versus current profits because there are none, and the company is mainly valued on its experimental pipeline.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer